
    
      An Open-label, Single or Multiple-dose, Fixed-sequence, 3-treatment, 3-Period phase 1 study
      to Evaluate the Pharmacokinetic/Pharmacodynamic Interactions and Safety between ID1801 and
      ID1803 in Healthy Male Subjects
    
  